Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
Aptar's Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate [Yahoo! Finance]
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™